- Home
- AGEN vs PEPG Comparison
AGEN vs PEPG Comparison
Compare AGEN & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- PEPG
- Stock Information
- Founded
- AGEN 1994
- PEPG 2018
- Country
- AGEN United States
- PEPG United States
- Employees
- AGEN N/A
- PEPG N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- AGEN Health Care
- PEPG Health Care
- Exchange
- AGEN Nasdaq
- PEPG Nasdaq
- Market Cap
- AGEN 52.6M
- PEPG 52.4M
- IPO Year
- AGEN 2000
- PEPG 2022
- Fundamental
- Price
- AGEN $3.40
- PEPG $1.36
- Analyst Decision
- AGEN Buy
- PEPG Buy
- Analyst Count
- AGEN 4
- PEPG 3
- Target Price
- AGEN $8.33
- PEPG $9.67
- AVG Volume (30 Days)
- AGEN 1.0M
- PEPG 228.0K
- Earning Date
- AGEN 05-12-2025
- PEPG 05-08-2025
- Dividend Yield
- AGEN N/A
- PEPG N/A
- EPS Growth
- AGEN N/A
- PEPG N/A
- EPS
- AGEN N/A
- PEPG N/A
- Revenue
- AGEN $99,524,000.00
- PEPG N/A
- Revenue This Year
- AGEN $14.67
- PEPG N/A
- Revenue Next Year
- AGEN N/A
- PEPG N/A
- P/E Ratio
- AGEN N/A
- PEPG N/A
- Revenue Growth
- AGEN N/A
- PEPG N/A
- 52 Week Low
- AGEN $1.38
- PEPG $0.88
- 52 Week High
- AGEN $19.69
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- AGEN 65.81
- PEPG 45.45
- Support Level
- AGEN $2.83
- PEPG $1.46
- Resistance Level
- AGEN $4.06
- PEPG $1.66
- Average True Range (ATR)
- AGEN 0.33
- PEPG 0.16
- MACD
- AGEN 0.03
- PEPG 0.00
- Stochastic Oscillator
- AGEN 54.20
- PEPG 41.18
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.